Meta-analysis of randomized trials, heterogeneity and prediction intervals;Metaanálisis de ensayos clínicos aleatorizados, heterogeneidad e intervalos de predicción

Medicina Clinica

Volumn 142, Issue 6, 2014, Pages 270-274

  Catalá López, Ferrán ^a,b,c   Tobías, Aurelio ^d  

^a Division de Farmacoepidemiologia y Farmacovigilancia   (Spain)

^b Fundacion Instituto de Investigacion en Servicios de Salud   (Spain)

^c Research Network on Health Services in Chronic Diseases   (Spain)

^d INSTITUTE OF ENVIRONMENTAL ASSESSMENT AND WATER RESEARCH   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; HUMAN; MEDICAL RESEARCH; META ANALYSIS (TOPIC); PREDICTION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANGIOTENSIN RECEPTOR ANTAGONISTS; CARDIOVASCULAR DISEASES; CONFIDENCE INTERVALS; DIABETES COMPLICATIONS; HEART FAILURE; HUMANS; META-ANALYSIS AS TOPIC; MODELS, THEORETICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVIEW LITERATURE AS TOPIC; RISK; TREATMENT OUTCOME;

EID: 84896697759     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2013.06.013     Document Type: Article

References (17)

1. F. Catalá-López, and A. Tobías Síntesis de la evidencia clínica y metaanálisis en red con comparaciones indirectas Med Clin (Barc) 140 2013 182 187
2. I. Ferreira González, G. Urrútia, and P. Alonso-Coello Revisiones sistemáticas y metaanálisis: bases conceptuales e interpretación Rev Esp Cardiol 64 2011 688 696
3. G. Urrútia, and X. Bonfill Declaración PRISMA: una propuesta para mejorar la publicación de revisiones sistemáticas y metaanálisis Med Clin (Barc) 135 2010 507 511
4. D. Moher, and A. Liberati Revisiones sistemáticas y metaanálisis: la responsabilidad de los autores, revisores, editores y patrocinadores Med Clin (Barc) 135 2010 505 506
5. D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement PLoS Med 6 2009 e1000097
6. A. Liberati, D.G. Altman, J. Tetzlaff, C. Mulrow, P.C. Gøtzsche, and J.P. Ioannidis et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration PLoS Med 6 2009 e1000100
7. J.P. Higgins, S.G. Thompson, and D.J. Spiegelhalter A re-evaluation of random-effects meta-analysis J R Stat Soc Ser A Stat Soc 172 2009 137 159
8. R.D. Riley, J.P. Higgins, and J.J. Deeks Interpretation of random effects meta-analyses BMJ 342 2011 d549
9. R. DerSimonian, and N.M. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
10. J.P. Higgins, S.G. Thompson, J.J. Deeks, and D.G. Altman Measuring inconsistency in meta-analyses BMJ 327 2003 557 560
11. S.G. Thompson Why sources of heterogeneity in meta-analysis should be investigated BMJ 309 1994 1351 1355
12. T.B. Huedo-Medina, J. Sánchez-Meca, F. Marín- Martínez, and J. Botella Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods 11 2006 193 206
13. J.P. Higgins Commentary: Heterogeneity in meta-analysis should be expected and appropriately quantified Int J Epidemiol 37 2008 1158 1160
14. W.G. Cochran The combination of estimates from different experiments Biometrics 10 1954 101 129
15. J. Sánchez-Meca, and F. Marín-Martínez Confidence intervals for the overall effect size in random-effects meta-analysis Psychol Methods 13 2008 31 48
16. C. Guddat, U. Grouven, R. Bender, and G. Skipka A note on the graphical presentation of prediction intervals in random-effects meta-analyses Syst Rev 1 2012 34
17. S. Bangalore, S. Kumar, J. Wetterslev, and F.H. Messerli Angiotensin receptor blockers and risk of myocardial infarction: Meta-analyses and trial sequential analyses of 147 020 patients from randomised trials BMJ 342 2011 d2234